Lilly's Alzheimer's Drug Kisunla To Cost $32K For First Year, $12,522 For 6-Month Course, And $695.65 Per Vial
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's new Alzheimer's drug, Kisunla, will be priced at $32,000 for the first year, $12,522 for a 6-month course, and $695.65 per vial. This pricing strategy could impact the company's revenue and stock performance.
July 02, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's new Alzheimer's drug, Kisunla, is priced at $32,000 for the first year, $12,522 for a 6-month course, and $695.65 per vial. This pricing strategy could significantly boost the company's revenue and positively impact its stock price in the short term.
The high pricing of Kisunla suggests a potential for significant revenue generation for Eli Lilly. Given the demand for Alzheimer's treatments, this could lead to a positive impact on LLY's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100